ResMed

Q1 FY2027
Speakers

Oct 29, 2026 · 63 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Welcome to the Q1 fiscal year 2027 ResMed Earnings Conference Call. ?My name is Shamali and I will be your operator for today's call. At this time, all participants are in listen-only mode. Also, please note this conference call is being recorded. Later, we will conduct a question and answer session. Let me hand over the call to Sally Schwartz, Res Med's Chief Investment Relations Officer.

Passages & reports (3)
  • Welcome to the Q1 fiscal year 2027 ResMed Earnings Conference Call.
  • My
  • name is Shamali and I will be your operator for today's call. At this time, all participan…

Speaker 1

Unverified voice label

Thanks, Shamali. I want to welcome our listeners to ResMed's first quarter fiscal year 2027 earnings call. ?We are live webcasting this call, and the replay will be available on the investor relations section of our corporate website later today. Our earnings press release is available online now. As with last quarter, we will be displaying our earnings presentation during our prepared remarks, ?and then we will post the slides to our IR website after the conclusion of our remarks.

During today's call, we will discuss several non GAP measures that we believe provide useful information for investors. This information is not intended to be considered in isolation or as a substitute for GAAP financial information. We encourage you
to review the supporting schedules in today's earnings press release to reconcile these non-GAAP measures with the GAAP reported numbers. In addition, our discussion today will include forward-looking statements, including, but not limited to, expectations about our future financial and operating performance.

We make these statements based on
reasonable assumptions. However, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today. ?And with that, I'll now turn the call over to Mick.

Passages & reports (9)
  • Thanks, Shamali. I want to welcome our listeners to ResMed's first quarter fiscal year 202…
  • We
  • are live webcasting this call, and the replay will be available on the investor relations …
  • and
  • then we will post the slides to our IR website after the conclusion of our remarks. During…
  • to review the supporting schedules in today's earnings press release to reconcile these no…
  • reasonable assumptions. However, our actual results could differ. Please review our SEC fi…
  • And
  • with that, I'll now turn the call over to Mick.

Speaker 2

Unverified voice label

Great. Thanks, Sally, and welcome to all. We're all together here in uh Sydney, Australia, and uh and all fired up at uh 7 30 in the morning. Um during the first quarter of our fiscal year 2027, we delivered another strong set of results. ?Uh 7% revenue growth on a core constant currency basis on the top line, 50 basis points of year over year gross margin expansion, and 14% growth on the bottom line in non gap earnings per share.

We also returned more than $1 billion to our shareholders during the quarter through both our quarterly dividend and
our share repurchase, funded with the Matrix Care Business Divestiture proceeds and cash on hand. ResMed's fiscal year 2027 is off to an excellent start. like to take this opportunity to thank the Global ResMed team for their unwavering dedication to our patients, our providers, and physicians.

Passages & reports (4)
  • Great. Thanks, Sally, and welcome to all. We're all together here in uh Sydney, Australia,…
  • Uh
  • 7% revenue growth on a core constant currency basis on the top line, 50 basis points of ye…
  • our share repurchase, funded with the Matrix Care Business Divestiture proceeds and cash o…

We're building the world's leading digital health ecosystem, encompassing sleep health, breathing health, and healthcare technology delivered in the home. As we move throughout our fiscal year 2027, we're focused on three key areas. One, on our continued innovation and operational excellence to support ResMed's ongoing growth and transformation work, two, on active portfolio management across our business lines, and three, on leveraging our significant free cash flow to both reinvest in our business and return capital to shareholders.

ResMed is committed to innovation
excellence across the sleep health ecosystem. This means ongoing innovation in our products and bringing together devices, masks, digital tools, and provider support to create a more connected therapy experience and to help people stay engaged with their therapy over time. Last quarter I talked about the launch of the AirCurve 11 ST and STA platforms into the US market.

The ST and the STA are bi-level device platforms for patients who need more pressure support or have more complicated breathing disorders, including central sleep apnea, complex sleep apnea, and
COPD plus OSA, which is known clinically as Overlap Syndrome. ?The Air Curve 11 is built on our market leading Air 11 platform that has CPAPs, APAPs, and now these advanced BI levels, allowing us to leverage a shared technology and digital health ecosystem across a broader range of patient populations.

This helps simplify workflows for providers while creating a more consistent experience for
patients. We've also launched just this week a third fabric mask into the market. We call it the AirTouch F, F for Fred 40 ?in the US. AirTouch F 40 brings ResMed's proprietary comfy soft fabric cushion to a minimalist design that is intended to adapt to a person's facial contours dynamically as they move throughout the night. ?

In
a ResMed study, 91% of patients rated the AirTouch F 40 as comfortable or very comfortable at initial fitting. This technology can help patients get adherent with less provider effort and can drive patient and provider preference for S-Men products. On our most recently launched fabric masks, we have now shown 6% increase in therapy adherence for the fabric masks versus their silicone mask equivalent.

This is market leading technology, and we continue to bring these products to market. Watch this space.
?On the software side, we recently launched a refresh of our MyAir Patient app. We're now well over 13 million downloads of our MyAir app, and we'll talk about that later. But in addition to the enhanced user interface on MyAir and the optional dark mode, new features include an updated MyAir score, a nightly timeline of events, and therapy control to adjust comfort settings from the app, giving each user a more personalized experience.

MyAir now also includes a service that we call Equipment Care, and it's launched in a number of geographies. And it makes it easier for patients to request resupply by showing a visual
countdown for each mask or other device accessory. It can send timed reminders when masks and accessories are eligible for replacement, helping encourage action by patients and increasing convenience for the patient and making it easier for the provider.

Watch this space as we increase availability of this type of service for consumers who want
to access better resupply. Also on the Maya app, our generative AI-powered digital sleep coach that we call Dawn has now seen more than 2.1 million inquiries from patients already on therapy. That's up over 40% just from last quarter. This demonstrates that patients are very curious about their CPAP therapy and they want to learn ?more.

Dawn helps patients find support wherever and whenever they need it, significantly reducing customer service inquiries to ResMed, but also reducing customer service inquiries to ResMed's HME partners channel partners. Delighting patients and saving costs for HMEs is a double win for ResMed through this innovative Gen
AI tech.

Passages & reports (22)
  • We're building the world's leading digital health ecosystem, encompassing sleep health, br…
  • ongoing growth and transformation work, two, on active portfolio management across our bus…
  • excellence across the sleep health ecosystem. This means ongoing innovation in our product…
  • talked about the launch of the AirCurve 11 ST and STA platforms into the US market. The ST…
  • COPD plus OSA, which is known clinically as Overlap Syndrome.
  • The
  • Air Curve 11 is built on our market leading Air 11 platform that has CPAPs, APAPs, and now…
  • patients. We've also launched just this week a third fabric mask into the market. We call …
  • in
  • the US. AirTouch F 40 brings ResMed's proprietary comfy soft fabric cushion to a minimalis…
  • In
  • a ResMed study, 91% of patients rated the AirTouch F 40 as comfortable or very comfortable…
  • masks, we have now shown 6% increase in therapy adherence for the fabric masks versus thei…
  • On
  • the software side, we recently launched a refresh of our MyAir Patient app. We're now well…
  • of events, and therapy control to adjust comfort settings from the app, giving each user a…
  • countdown for each mask or other device accessory. It can send timed reminders when masks …
  • to access better resupply. Also on the Maya app, our generative AI-powered digital sleep c…
  • demonstrates that patients are very curious about their CPAP therapy and they want to lear…
  • more.
  • Dawn helps patients find support wherever and whenever they need it, significantly reducin…
  • AI tech.

Speaker unclear

?We

Passages & reports (1)
  • We

Speaker 2

will continue to evolve MyAir based on consumer and provider feedback. Our aim is to bring clearer therapy insights, to bring more intuitive support, and to bring increasingly personalized experience to engage patients throughout their therapy journey. Together with AirView, ResMed's remote monitoring platform for healthcare providers, MyAir has been shown to meaningfully improve therapy compliance from 70% up to 87%, just by adding MyAir for the patient.

One further update regarding our FDA cleared AI enabled digital medical device that we call Smart
Comfort. We launched this just earlier this calendar year. Smart Comfort was built on millions and millions of nights of ResMed sleep data to recommend personalized adjustments to comfort settings like temperature, humidity, and it's and it's applied on new AirSense 11 users. We predicted in previous quarters that increased comfort could lead to increased adherence.

And it turns out that prediction has come true. Early real-world data shows a 4.3% increase in 30-day compliance versus the device's default settings. Smart Comfort has been selected as
a special mention in Time magazine's best inventions of 2026. But it more important than that, it's evolving our products to deliver increasingly personalized therapy to patients, and it's a winning use case for AI.

Resmed's digital health ecosystem is second to none, providing sustainable value for patients, for
physicians, for providers, even for payers and beyond. ?On the operational excellence side, we were able to execute some of our planned supply chain initiatives more quickly than we'd predicted. We're able to rephase some of our planned expansion initiatives, particularly in Indianapolis, Indiana, allowing us to exceed our own expectations for gross margin for the quarter.

The transformational pipeline of
initiatives, what I call our productivity pipeline for our supply chain team, they built it and it remains robust and multi year, underpinning our ongoing confidence that we can deliver double digit basis points improvements in gross margin every year, every fiscal year through 2030. I'm also proud to share that we've produced our first made in America CPAP device, an Essence 11, has come off the line at our Atlanta, Georgia facility.

Having this capability for U.S. manufacturing gives ResMed additional flexibility to optimize operations as needed across our global manufacturing footprint. We
also continue progress on our new Indiana Indianapolis based distribution center, which, once it's fully operational, will enable faster delivery to our North American customers. Resmed has a significant and growing U.S. manufacturing presence, and we continue to invest in expanding our capability to serve our highest volume market.

With regard to our government advocacy work, I can tell you that we are actively engaged with the U.S. government as well as industry partners to support policies that strengthen domestic U.S. manufacturing and global supply chain resilience, while protecting patient access to our life saving therapy in the US
and around 144 countries worldwide. Alongside these developments in the US, we are expanding our Asia manufacturing capabilities, including at our largest manufacturing facility in Singapore, and our facilities in Malaysia that are joined to the Singapore operation.

Together with our Sydney, Australia, Calabasas, California,
Atlanta, Georgia, and our newly established Indianapolis, Indiana facilities, our global operations footprint positions us extremely well to serve our growing customer base and patients around the world. Over the past quarters, I've highlighted our initiatives to increase awareness of sleep apnea and the impact that chronic poor sleep has both on the individuals and healthcare system, but also on their partners and families and workmates.

As you know, we've been excited to see growing appreciation of the importance of sleep health, driven by consumer wearables, including Samsung Galaxy Ring, that just this week, I think actually overnight, uh
got FDA clearance for sleep apnea detection from their Samsung Galaxy Ring. But also from Big Pharma ?and the GLP1s, the investment that particularly Lily is making, but also Nova and driving patients into primary ?care.

Earlier this month, we announced a collaboration with Smart Mattress sensor maker 8Sleep. Their Eight Sleep Pod users in both the US and Australia markets will be able to securely connect their MyAir Sleep Insights to the ATSleep app, giving them a more complete picture
of their sleep health. Here in Australia, ATSleep users whose sleep data shows trends such as heavy snoring may be guided to ResMed's sleep health resources, including sleep assessments and the pathway to diagnosis and therapy and beyond.

This consumer sleep wellness
collaboration adds to our partnership with Smart RingMaker Aura that I discussed during ResMed's last earnings call. We've continued to see strong traffic to Resmed's website from Aura app users. As of September 30, approximately 28,000 Aura users, more than double what we had seen at the end of July, have come to resmed.com from a customized tile within Aura's own app.

Many thousands of those users have taken the ResMed sleep assessment right there on Resmed.com. Approximately 72% of those assessed identified themselves as previously
undiagnosed for OSA, highlighting the potential to turn sleep insights into action and helping more people get evaluated and ultimately treated for their sleep apnea. Another sleep pathway enabler are these new medicines, well, not so new, maybe 10-15 years in the market, but newly ramping up GLP1s.

As we've discussed before, patients on GLP1s both initiate CPAP therapy more and stay on CPAP therapy longer, and they buy more stuff.
?As an update to our analysis that's built from a claims database of tens of millions of patients, our specifically analyzed cohort now includes more than 3.3 million de-identified patients. We are still seeing that patients who have scripts for both CPAP and GLP1s are more than 11% more likely to start on CPAP therapy than patients who have a script for CPAP alone.

They are also more than 3% more likely to have a resupply event at one year and more than 7% more likely to have a resupply event at three years. The CPAP plus GLP1 and the CPAP only cohorts are
measured on the same basis, i.e., patients who stop CPAP remain in the base population for both groups. Sleep apnea risk factors include age, gender, craniofacial geometry, as well as weight.

OSA very often needs to be treated even after very significant weight loss,
as we've seen in the clinical literature, the real-world data that we show, and in the numbers if you look at our incredible mass growth over time. Resmond continues to selectively invest in marketing that expands our awareness, reduces barriers to diagnosis and treatment, and helps more people understand the life-changing impact of better sleep, better breathing.

You may have seen some of our campaigns underway. I'll highlight just three of them quickly here on our call. Number one, our so-called CPAP baddies campaign is helping normalize CPAP therapy through authentic community-driven conversations, making treatment more approachable and
encouraging more people to start and say stay on therapy. It's really creating a CPAP community of people who are proud of changing their lives.

Number two, our In Bed With interview series features sleep doctors, sleep physicians, and other sleep wellness thought leaders to help more people recognize
symptoms of sleep apnea, to seek care, and ultimately to improve long term clinical outcomes as well as quality of life outcomes. And thirdly, and finally, our athletic partnerships, most recently with a NASCAR driver Tyler Reddick, enable us to reach new audiences with powerful real world stories that demonstrate how effective sleep therapy can improve energy, performance, and personal and family life.

It's interesting. The most watched episode featuring Tyler Reddick, who's a world-class professional driver, was not about his improvement in sports performance and winning the Daytona 500 in the first three NASCAR races of the
season, creating new sports records for that sport. The most watched podcast and viral social media was about his wife, Alexa, sharing that Resmed CPAP treatment made him a better husband, a better father, and a better friend.

The words from patient one back here in Australia in
1989, Eddie Merck, who said, This therapy saved my marriage, saved my job, saved my life, come to mind. It's great to have that story retold from many perspectives and from a young race car driver here right in 2026. Okay, together these sort of consumer engagement initiatives are helping ResMed interact with more people, driving greater awareness and adoption.

And ultimately, they fulfill our mission of improving lives through better sleep and better breathing, longer life, which is longevity, lifespan, but more importantly, health span, which is living longer with a good quality of life. Greater awareness in the clinical community is another key element
to ensuring consumers have ready access to information and pathways to diagnosis and therapy. Our continuing medical education or CME programs include sleep medicine physician society approved guidelines.

Obviously, that includes the benefits of CPAP, APAP, and Bilevel Therapy as the clinical gold standard, the
frontline treatment for any patient diagnosed with sleep apnea. ?Our sleep apnea education courses have now been completed by approximately 108,000 times by more than 63,000 unique clinicians. We've been tracking the number of referrals for home sleep apnea tests and prescriptions for positive airway pressure both before and after training.

It's great to see that post-training, these clinicians are not only saying they intend to change their clinical practices, they are actually changing them and it's impacting patient flow. Okay, our second priority is active portfolio management. On September 1st, we closed on the divestiture of our matrix care business. We continue
to expect this move to accelerate the growth and profitability of our core residential care or RCS business.

For fiscal year 2027, we are still planning for our RCS business to deliver high single digit revenue growth with operating leverage reflecting both improved mix and execution
focus. We're off to a solid start with high single digit growth powered by our Bright Tree and Medifox Darn product lines. We're also making good early progress integrating our NEEDRA or Restless Legs Syndrome Therapy that we acquired with a company that was called Noctrix from the Stanford's Biodesign Incubator.

NIDRA's commercial footprint is expanding rapidly, albeit from a small base. We're keenly focused on increasing commercial coverage for NIDRA and supporting expanded access to this novel, non invasive, sleep physician prescribed, DME channel delivered,
VA channel delivered to patients therapy. Prioritizing patient care is also central to our ongoing astral field safety corrective action. We're responsibly supporting patients, including patient-centric and quality-focused completion of the ongoing action.

We also recognize that home care provider customers need to be able to plan for future
ventilation needs. That commitment is why we recently announced that we will no longer sell the astral device. We're focusing all available components to service astral devices for existing patients, with prioritization based on the highest clinical acuity and guided by clinical judgment. We're going to execute the best recall in the history of life support ventilation.

We took $42 million reserve, and I've seen the latest data, and it's very good. We're executing very well in that field safety notice. We intend to keep allocating capital towards our high growth, high return opportunities. This allows us to accelerate the expansion of our digital health ecosystem to support continued
innovation at scale and to drive strong progress towards successful execution of our 2030 strategy.

Excuse

Passages & reports (49)
  • will continue to evolve MyAir based on consumer and provider feedback. Our aim is to bring…
  • platform for healthcare providers, MyAir has been shown to meaningfully improve therapy co…
  • Comfort. We launched this just earlier this calendar year. Smart Comfort was built on mill…
  • predicted in previous quarters that increased comfort could lead to increased adherence. A…
  • a special mention in Time magazine's best inventions of 2026. But it more important than t…
  • physicians, for providers, even for payers and beyond.
  • On
  • the operational excellence side, we were able to execute some of our planned supply chain …
  • initiatives, what I call our productivity pipeline for our supply chain team, they built i…
  • that we've produced our first made in America CPAP device, an Essence 11, has come off the…
  • also continue progress on our new Indiana Indianapolis based distribution center, which, o…
  • serve our highest volume market. With regard to our government advocacy work, I can tell y…
  • and around 144 countries worldwide. Alongside these developments in the US, we are expandi…
  • Atlanta, Georgia, and our newly established Indianapolis, Indiana facilities, our global o…
  • that chronic poor sleep has both on the individuals and healthcare system, but also on the…
  • got FDA clearance for sleep apnea detection from their Samsung Galaxy Ring. But also from …
  • and
  • the GLP1s, the investment that particularly Lily is making, but also Nova and driving pati…
  • care.
  • Earlier this month, we announced a collaboration with Smart Mattress sensor maker 8Sleep. …
  • of their sleep health. Here in Australia, ATSleep users whose sleep data shows trends such…
  • collaboration adds to our partnership with Smart RingMaker Aura that I discussed during Re…
  • July, have come to resmed.com from a customized tile within Aura's own app. Many thousands…
  • undiagnosed for OSA, highlighting the potential to turn sleep insights into action and hel…
  • ramping up GLP1s. As we've discussed before, patients on GLP1s both initiate CPAP therapy …
  • As
  • an update to our analysis that's built from a claims database of tens of millions of patie…
  • on CPAP therapy than patients who have a script for CPAP alone. They are also more than 3%…
  • measured on the same basis, i.e., patients who stop CPAP remain in the base population for…
  • as we've seen in the clinical literature, the real-world data that we show, and in the num…
  • sleep, better breathing. You may have seen some of our campaigns underway. I'll highlight …
  • encouraging more people to start and say stay on therapy. It's really creating a CPAP comm…
  • symptoms of sleep apnea, to seek care, and ultimately to improve long term clinical outcom…
  • demonstrate how effective sleep therapy can improve energy, performance, and personal and …
  • season, creating new sports records for that sport. The most watched podcast and viral soc…
  • 1989, Eddie Merck, who said, This therapy saved my marriage, saved my job, saved my life, …
  • interact with more people, driving greater awareness and adoption. And ultimately, they fu…
  • to ensuring consumers have ready access to information and pathways to diagnosis and thera…
  • frontline treatment for any patient diagnosed with sleep apnea.
  • Our
  • sleep apnea education courses have now been completed by approximately 108,000 times by mo…
  • It's great to see that post-training, these clinicians are not only saying they intend to …
  • to expect this move to accelerate the growth and profitability of our core residential car…
  • focus. We're off to a solid start with high single digit growth powered by our Bright Tree…
  • the Stanford's Biodesign Incubator. NIDRA's commercial footprint is expanding rapidly, alb…
  • VA channel delivered to patients therapy. Prioritizing patient care is also central to our…
  • ventilation needs. That commitment is why we recently announced that we will no longer sel…
  • life support ventilation. We took $42 million reserve, and I've seen the latest data, and …
  • innovation at scale and to drive strong progress towards successful execution of our 2030 …

Speaker unclear

?me.

Passages & reports (1)
  • me.

Speaker 2

In addition to investing in our business through continued innovation, partnerships and MA, we're also maximizing the return of capital to our shareholders. During the first quarter, we bought back approximately $936 million of our stock through a combination of open market repurchase and an accelerated share repurchase program using the proceeds from our matrix care business to vestiture. Together with our dividend, we returned more than $1 billion to our shareholders this quarter. ?

This
is a record for ResMed and reflects our conviction that investing in our company is is a compelling, high return on investment opportunity. ?Before I turn the call over to Aaron, I'd like to take this opportunity to thank Ron Taylor, ResMed's current uh lead independent board director. He recently announced that his retirement after more than 21 years of service, Ron will not stand for reelection at our upcoming annual general meeting of stockholders, which will be held on November 18, 2026.

During his tenure, Ron helped guide ResMed's governance and strategy, providing thoughtful leadership and independent oversight during a period of significant growth and transformation for the company. Ron's integrity, sound judgment, and unwavering commitment to our patients' employees and as a representative shareholders helped ResMed stay what it is, which is
a strong company innovating and driving growth. ?My fellow board members and I have appointed Carol Burt to serve as our next lead independent director, effective November 15.

Carol has served on ResMed's board since 2013 and currently chairs the Nom and Gov Committee. She's also a member of the Audit Committee as well as the Compliance, Privacy and Quality Committee. Carol's extensive
board leadership experience, extensive governance experience, and extensive healthcare industry, including payer knowledge, position her very well to serve as ResMed's next lead director. I look forward to continuing to work closely with Carol and the entire board as we advance our strategy and create long-term value for our shareholders. ?

Let
me close with this. ResMed has a tremendous market opportunity, a leading market position, a very strong balance sheet, and a strong track record of successful execution. We remain very excited about our 2030 strategy and we're confident in our five year outlook that features high single digit top line revenue growth and bottom line earnings growth that's higher than revenue growth with leverage.

We are committed to keep delivering to the benefit of all of our stakeholders and most importantly for the number one stakeholder, our patients.
?With that, I'll turn the call over to Aaron to go through a deeper dive into our financials and then we'll open up the floor for QA. Aaron.

Passages & reports (16)
  • In addition to investing in our business through continued innovation, partnerships and MA…
  • proceeds from our matrix care business to vestiture. Together with our dividend, we return…
  • This
  • is a record for ResMed and reflects our conviction that investing in our company is is a c…
  • Before
  • I turn the call over to Aaron, I'd like to take this opportunity to thank Ron Taylor, ResM…
  • on November 18, 2026. During his tenure, Ron helped guide ResMed's governance and strategy…
  • a strong company innovating and driving growth.
  • My
  • fellow board members and I have appointed Carol Burt to serve as our next lead independent…
  • board leadership experience, extensive governance experience, and extensive healthcare ind…
  • Let
  • me close with this. ResMed has a tremendous market opportunity, a leading market position,…
  • line earnings growth that's higher than revenue growth with leverage. We are committed to …
  • With
  • that, I'll turn the call over to Aaron to go through a deeper dive into our financials and…

Speaker 3

Unverified voice label

Great. Thanks, Mick. In my remarks today, I will provide an overview of our results for the fiscal quarter of for the first quarter of fiscal year 2027. Unless otherwise noted, all comparisons are to the prior year quarter and on a non-gap basis in core constant currency terms where applicable. We encourage you to review the updated, detailed layout for our reconciliation of the non-GAP to GAAP numbers in our first quarter earnings press release.

We had a good start to our fiscal year 2027. Total revenue for the first quarter was $1.4 billion, a 6% increase on a reported basis, and 7% increase on a core constant currency
basis. ?As a reminder, core constant currency excludes our acquisition of the NESIA restless leg syndrome therapy and includes only two months of the matrix care business revenue in both fiscal years 2026 and 2027.

Growth in the quarter reflected solid demand across devices, masks, and our remaining
RCS business. Non GAAP earnings per share increased by 14% to $2.91 per share. Moving to revenue by business and geography, starting in the Americas, sleep device revenue increased by 6%, life support device revenue declined by 94%, and masks and other revenue increased by 10%.

Passages & reports (7)
  • Great. Thanks, Mick. In my remarks today, I will provide an overview of our results for th…
  • review the updated, detailed layout for our reconciliation of the non-GAP to GAAP numbers …
  • basis.
  • As
  • a reminder, core constant currency excludes our acquisition of the NESIA restless leg synd…
  • RCS business. Non GAAP earnings per share increased by 14% to $2.91 per share. Moving to r…
  • revenue increased by 10%.

Speaker unclear

?In

Passages & reports (1)
  • In

Speaker 3

the rest of the world, sleep device revenue increased by 13%, life support device revenue declined by 79%, and masks and other revenue increased by 11%. Rest of world sleep device growth in the quarter was supported in part by a fleet refresh in France, which is weighted towards the first half of the fiscal ?year. The total contribution from pricing was minimal this quarter. ?

In
the appendix of our earnings presentation, we've provided historical revenue figures for both sleep devices and life support devices. Residential care software revenue declined by 7% in the first quarter on a headline reported basis and increased 5% on a constant currency basis. Removing the matrix care business that we've now divested, the remaining businesses of RCS, Bright Tree and Medifox Dan, increased by 8%.

Non-GAP gross margin was 62.5% in the first quarter, up 50 basis points year over
?year. The quarter's results was driven by productivity gains across procurement, manufacturing, and distribution, along with favorable product mix, more than offsetting foreign exchange headwinds. Versus our initial expectations, our Q1 gross margin benefited from the phasing of supply chain expansion investments, primarily related to the continued build-out of our new U.S.

facility in Indiana. We continue to experience the impacts of inflation, especially in some of our electronic components, and expect these impacts to build throughout the remainder of the fiscal year.
?We are very proud of the work our supply chain team is doing to drive productivity and efficiencies despite the current inflationary environment. Moving on to operating expenses, non-GAAP RD expenses for the first quarter increased by 16% on a reported basis and 14% on a constant currency basis.

RD expenses were roughly flat
sequentially, excluding the impact of matrix ?care. The year-over-year increase was primarily driven by continued investment in our next generation device and mask platforms, along with expanded development of AI-enabled tools that streamline the patient journey, helping patients start therapy sooner and stay on it longer. ?Non GAP SGNA expenses for the first quarter increased by 6% on a reported basis and constant currency basis. ?

The
Q1 increase reflected investments we're making to drive growth, including marketing campaigns, ?and by NIDRA, partially offset by productivity gains that were driving in our support functions. ?As you saw in the earnings release, during the quarter we recorded restructuring and transformation related charges of approximately $29 million, as well as approximately $10 million of acquisition and investment related expenses associated with the matrix care business.

We are embarking on an exciting growth and transformation journey. This quarter we
identified early opportunities to address straighted costs. We'll have more to say on this effort and the benefits we expect to recognize in the coming quarters. Non-gap operating margin for the quarter was 35.8%, down 30 basis points year over year. ?Net interest income for the quarter was 16 million, primarily driven by the ongoing benefit from the Singapore Net Investment Hedge.

Net other income also reflected a gain of approximately $6 million from our ownership stake in APNED as a result of its initial public offering. Our non GAAP effective tax rate for the first quarter
was 21.2%, compared with 22.3% in the prior year quarter, reflecting a more favorable jurisdiction mix of earnings. ?Non GAP diluted earnings per share increased by 14% to $2.91, driven primarily by revenue growth, gross margin expansion, and a lower diluted share count.

This growth was partially offset by an approximate five cent headwind from the Matrix Care Devestiture and NITRA acquisition, as well as an approximate eight
cent headwind related to movements and foreign exchange rates. Free cash flow for the quarter was $374 million, down year over year, primarily driven by higher inventory levels that we have strategically built in light of the external environment and an increase in cash tax prepaids.

Between fiscal year 2025
and 2026, we received significant U.S. tax refunds, which were netted against prepaids in the presentation of Free Cash Flow. This quarter represents our expected steady state for prepaids moving forward. ?We ended the first quarter with a cash balance of approximately $1 billion. During the quarter, our share repurchases totaled $936 million. Along with our dividend, we returned more than $1 billion to our shareholders in Q1, a more than four-fold increase over Q1 fiscal 2026.

Turning to guidance, as a reminder, for
fiscal year 2027, we are now providing full year revenue or full year guidance for revenue and non-GAP earnings per share on both a core constant currency and reported basis. We are pleased with our solid start to fiscal year 2027 and are reiterating our full year revenue and earnings per share guidance. We continue to expect year over year revenue growth in the range of 5 to 7% on a core constant currency basis.

As a reminder, this includes an approximately 130 basis point headwind or around $75 million stemming from our decision to no longer sell Astra. Astral When excluding the impact of Astral, our
core constant currency revenue growth would range from 6.3 to 8.3%. There are several key assumptions underpinning our revenue guidance. First, net price realization as we continue to roll out global pricing increases we discussed last quarter.

Second, successful execution and impact
from our new marketing campaigns that Mick shared in his remarks. Third, expected back half pressure in our rest of world sleep devices as the France fleet renewal concludes. And finally, the broader external environment, including the continued impact of inflation on our customers, which we will continue to monitor.

Passages & reports (36)
  • the rest of the world, sleep device revenue increased by 13%, life support device revenue …
  • year. The
  • total contribution from pricing was minimal this quarter.
  • In
  • the appendix of our earnings presentation, we've provided historical revenue figures for b…
  • the remaining businesses of RCS, Bright Tree and Medifox Dan, increased by 8%. Non-GAP gro…
  • year. The
  • quarter's results was driven by productivity gains across procurement, manufacturing, and …
  • facility in Indiana. We continue to experience the impacts of inflation, especially in som…
  • We
  • are very proud of the work our supply chain team is doing to drive productivity and effici…
  • sequentially, excluding the impact of matrix
  • care. The
  • year-over-year increase was primarily driven by continued investment in our next generatio…
  • Non
  • GAP SGNA expenses for the first quarter increased by 6% on a reported basis and constant c…
  • The
  • Q1 increase reflected investments we're making to drive growth, including marketing campai…
  • and
  • by NIDRA, partially offset by productivity gains that were driving in our support function…
  • As
  • you saw in the earnings release, during the quarter we recorded restructuring and transfor…
  • identified early opportunities to address straighted costs. We'll have more to say on this…
  • Net
  • interest income for the quarter was 16 million, primarily driven by the ongoing benefit fr…
  • was 21.2%, compared with 22.3% in the prior year quarter, reflecting a more favorable juri…
  • Non
  • GAP diluted earnings per share increased by 14% to $2.91, driven primarily by revenue grow…
  • cent headwind related to movements and foreign exchange rates. Free cash flow for the quar…
  • and 2026, we received significant U.S. tax refunds, which were netted against prepaids in …
  • We
  • ended the first quarter with a cash balance of approximately $1 billion. During the quarte…
  • fiscal year 2027, we are now providing full year revenue or full year guidance for revenue…
  • to expect year over year revenue growth in the range of 5 to 7% on a core constant currenc…
  • core constant currency revenue growth would range from 6.3 to 8.3%. There are several key …
  • from our new marketing campaigns that Mick shared in his remarks. Third, expected back hal…

Our core constant currency growth includes range guidance translates to reported revenue in the range of $5.75 billion to $5.85 billion. This assumes an approximately 60 basis point FX headwind based on rates as of quarter ?end. We still expect non gap earnings per share to be in the range of $12 to $12.25, an increase of approximately 7 to 10% on a reported basis.

Excluding the dilution from the divestiture of the matrix care business and the acquisition of NIDRA, guidance implies year over year core EPS growth would be in the
range of 12 to 14 percent. For gross margin, we still expect low double digit basis point margin expansion in fiscal year 2027. We may see some variability quarter to quarter based on inflationary impacts and timing of our supply chain initiatives and facility expansions.

Passages & reports (4)
  • Our core constant currency growth includes range guidance translates to reported revenue i…
  • end. We
  • still expect non gap earnings per share to be in the range of $12 to $12.25, an increase o…
  • range of 12 to 14 percent. For gross margin, we still expect low double digit basis point …

Our expectations for a slight increase in operating margin percentage in fiscal year 2027 remain unchanged. We are laser focused on achieving operating leverage by driving productivity and efficiency. This will enable us to reinvest back into high growth and high ROI opportunities in both RD and marketing. ?In Q1, we made significant progress towards returning more than $1.85 billion to shareholders over the course of fiscal year 2027, including both share repurchases and dividends.

This remains our expectation, and we will continue to be opportunistic with our repurchase activity as the year progresses. We still expect capital
expenditures in the range of 160 million to 180 million as we expand and further automate our U.S. and global manufacturing footprint to address the growing demand for our products. While we do not provide quarterly guidance, we would like to share some Q2 trends.

ResMed has historically experienced a mid-single-digit sequential increase in
total revenue from fiscal Q1 to Q2, and we expect a similar seasonal pattern to occur this year, excluding the two months of matrix care revenue that we had in Q1. ?We expect non GAP gross margin percent to be down slightly sequentially as certain expansion related costs impact us in Q2 rather than in Q1.

We also anticipate RD expenses to be largely flat from Q1 and SGA expenses to sequentially increase, tied to the marketing campaigns Mick referenced
earlier. ?We will continue to drive operating leverage across our support functions. We also expect net other income to be down roughly 10 million from Q1. Last quarter I shared my key priorities driving sustainable growth, supporting the continued transformation of ResMed, and maximizing return to shareholders.

We've made progress
on all three in Q1. ?The marketing campaigns and Mayer updates aimed at helping patients start and stay on therapy. Partnerships we've entered into with companies like ASleep and Aura to convert new patients entering into the funnel, and innovative new product launches such as the AirTouch S40 all support patients in their journeys towards better sleep health. At the same time, we're embracing change inside ResMed and creating a culture of continuous improvement, driving efficiencies, actively managing our portfolio, and selectively evaluating MA opportunities while leveraging AI and technology to transform and improve productivity. ?

We
also returned over a billion in cash to shareholders this quarter, a more than four increase over last year. Looking forward, we will continue to prioritize reinvestment in the business while maintaining our commitment to the dividend, opportunistic share repurchase, ?and an optimized capital structure. And with that, I will hand the call back over to Shamili.

Passages & reports (18)
  • Our expectations for a slight increase in operating margin percentage in fiscal year 2027 …
  • In
  • Q1, we made significant progress towards returning more than $1.85 billion to shareholders…
  • expenditures in the range of 160 million to 180 million as we expand and further automate …
  • total revenue from fiscal Q1 to Q2, and we expect a similar seasonal pattern to occur this…
  • We
  • expect non GAP gross margin percent to be down slightly sequentially as certain expansion …
  • earlier.
  • We
  • will continue to drive operating leverage across our support functions. We also expect net…
  • on all three in Q1.
  • The
  • marketing campaigns and Mayer updates aimed at helping patients start and stay on therapy.…
  • same time, we're embracing change inside ResMed and creating a culture of continuous impro…
  • We
  • also returned over a billion in cash to shareholders this quarter, a more than four increa…
  • and
  • an optimized capital structure. And with that, I will hand the call back over to Shamili.

Speaker 0

Thank you. As a reminder, please limit yourself to one question. And if you ask more than one, management will only answer the first question to help more analysts get their questions answered. Our first question comes from the line of Chris Cooper with JP Morgan. Please proceed with your question.

Passages & reports (1)
  • Thank you. As a reminder, please limit yourself to one question. And if you ask more than …

Questions & answers

Speaker 4

Unverified voice label

Maybe just perhaps for Aaron on the gross margin.

Passages & reports (1)
  • Maybe just perhaps for Aaron on the gross margin.

Speaker unclear

?So

Passages & reports (1)
  • So

Speaker 4

you were guided to a slight contraction year over year. You you came in somewhere ahead of that with a 50 basis point increase uh non-gap. I know last quarter you sort of alluded to it there. There was a lot of discussion on pricing. You you were keen to emphasize these increases were were very modest. And you also guided us, I think, to think that they don't really begin to benefit the PL until the second quarter.

So just wanted to understand have these price rises benefited earlier than expected? Should we think about further benefit building from here through the year? I think just at the end
there, you said there were some restructuring costs that moved from the first quarter to second quarter. So maybe just a bit more colour on what drove that gross margin uh ahead of expectation, please.

Passages & reports (3)
  • you were guided to a slight contraction year over year. You you came in somewhere ahead of…
  • very modest. And you also guided us, I think, to think that they don't really begin to ben…
  • there, you said there were some restructuring costs that moved from the first quarter to s…

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 3

Chris, so first, I mean, we have an unbelievable manufacturing and supply chain team. Um it it's obviously it's a very dynamic environment out there, and the team just continues to rise to the occasion and perform. Um it was really incredible to see firsthand a productivity pipeline that that continues to build and expand. Um we have hundreds of specific initiatives, and the team has really done a phenomenal job of building that culture of continuous improvement. ?

You know,
specific to Q1, you know, uh margins expanded about fifty basis points, and again, a testament to the productivity gains across ?the entire manufacturing and supply chain team. You know, we benefited a bit from the continued transition globally to Air Sense 11. Um we talked about uh slight FX headwinds that we ?had in the quarter. Um, but as mentioned in the prepared remarks, I think the biggest thing kind of that benefited us in in Q1 relative to expectations was just phasing from some of the timing of the supply chain expansion investments, primarily the the US build-out of our facility in Indiana.

Um and those costs
are now expected in Q2. And so that's the biggest factor. That's about a 30 basis point headwind quarter over quarter from Q1 to Q2. Price very much in line with what we expected to begin with. Very, very modest for the full year. And as I mentioned in prepared remarks, really no contribution from pricing in Q1. And we would expect that to build as we progress throughout the

Passages & reports (10)
  • Chris, so first, I mean, we have an unbelievable manufacturing and supply chain team. Um i…
  • Um we have hundreds of specific initiatives, and the team has really done a phenomenal job…
  • You know,
  • specific to Q1, you know, uh margins expanded about fifty basis points, and again, a testa…
  • the
  • entire manufacturing and supply chain team. You know, we benefited a bit from the continue…
  • had
  • in the quarter. Um, but as mentioned in the prepared remarks, I think the biggest thing ki…
  • are now expected in Q2. And so that's the biggest factor. That's about a 30 basis point he…
  • contribution from pricing in Q1. And we would expect that to build as we progress througho…

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker 0

Thank you. Our next question comes from the line of David Lowe with UBS. Please proceed with your

Passages & reports (1)
  • Thank you. Our next question comes from the line of David Lowe with UBS. Please proceed wi…

Speaker unclear

?question.

Passages & reports (1)
  • question.

Speaker 4

Thanks very much for taking my question. Could we just talk a little bit about the the rest of the world? We haven't heard from ResNet much in in in the past on what happens in some of the uh other lesser markets. And I see you've called out the France ?fleet renewals. If I could

Passages & reports (3)
  • Thanks very much for taking my question. Could we just talk a little bit about the the res…
  • fleet
  • renewals. If I could

Speaker unclear

?get you to talk and

Passages & reports (1)
  • get you to talk and

Speaker 5

Unverified voice label

give us a little bit of

Passages & reports (1)
  • give us a little bit of

Speaker unclear

?background on

Passages & reports (1)
  • background on

Speaker 4

that and whether there's any other

Passages & reports (1)
  • that and whether there's any other

Speaker unclear

?fleet

Passages & reports (1)
  • fleet

Speaker 5

renewal programs that ?we should be aware of, please.

Passages & reports (3)
  • renewal programs that
  • we should
  • be aware of, please.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

David, thanks for the question. Um yeah, look, Europe, Asia, rest of the world, uh 140 plus countries, so much going on there. But you know, uh with with sleep devices growing uh in the rest of the world at a plus thirteen percent, we thought it was very important to call out if we consider globally mid single digit growth in our devices, uh clearly there are, you know, a number of hundreds of basis points above that.

And so we wanted to call out what's happening in France. What happens there is there's differentiated reimbursement in France for a cloud connected CBAP versus a non-cloud connected CBAP. And
then when they reach their five-year life cycle, the uh the customers, the distributors there have to renew their fleets to make sure that their patients have uh the latest and greatest technology and that they get appropriate reimbursement for for the services they provide.

And and that uh renewal primarily from Essence 10 now
to Essence 11s uh has been ongoing in France for a while. Obviously, that is an S-curve and it goes for a while and then it then it plateaus out. And so we just felt what like it was important to call that out. And to your quick question and point, you know, we do have other fleet-based markets like Japan and a few others around the world.

Um and we will, you know, as appropriate when we see uh uh outperformance like that, call out what the outperformance is, what it looks like, and that we would normally expect sort of mid-single digit and global device revenue. Uh thanks
for the question, David. And uh, ?you know, we can go into more details as we see other areas and we will continue to highlight different countries and different things happening uh as they become material to the business and and and to our strategy.

Thanks for the question.

Passages & reports (8)
  • David, thanks for the question. Um yeah, look, Europe, Asia, rest of the world, uh 140 plu…
  • consider globally mid single digit growth in our devices, uh clearly there are, you know, …
  • then when they reach their five-year life cycle, the uh the customers, the distributors th…
  • to Essence 11s uh has been ongoing in France for a while. Obviously, that is an S-curve an…
  • have other fleet-based markets like Japan and a few others around the world. Um and we wil…
  • for the question, David. And uh,
  • you know,
  • we can go into more details as we see other areas and we will continue to highlight differ…

Speaker 0

Thank you. Our next question comes from the line of Craig Wine Pan with RBC Capital Markets. Please proceed with your question.

Passages & reports (1)
  • Thank you. Our next question comes from the line of Craig Wine Pan with RBC Capital Market…

Speaker unclear

?Ah, good morning. Um thanks, Mick,

Passages & reports (1)
  • Ah, good morning. Um thanks, Mick,

Speaker 5

for outlining all the marketing and partnership initiative ?that you're using to drive growth and awareness. I just wanted to understand if they provided much benefit in the quarter to your top line and when do you think they could provide a meaningful impact?

Passages & reports (3)
  • for outlining all the marketing and partnership initiative
  • that
  • you're using to drive growth and awareness. I just wanted to understand if they provided m…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

Craig, it's a it's a great question. And, ?you know, I I said this last quarter, I think I've said it every quarter the last uh number of years, which is you know, uh we have to fight uh for growth uh every quarter. And and a lot of that is in not so much top of funnel, which is awareness now around sleep suffocation, sleep apnea, how important it is to treat good sleep and good breathing for good health and lower cardiovascular risk, diabetes risk and sole cell tumor cancer risk, dementia, so on and so ?on.

It's middle of funnel where somebody has is aware from their watch, their wearable, or a pharma company that there's an issue and they turn up to that primary care physician. And so um you know, to your point, we we updated the CME numbers, lots of education happening there. We're tracking pre and post
that 63,000 unique clinicians in the primary care area, whether that's an NP, a PA, an MD, or or a nurse, are making sure that when they see the positive uh diagnosis, they walk that patient through the education and their pathway to gold standard therapy.

So it's very early days. I think on the
Aura partnership, we're in the tens of thousands. Eight Sleep, we just announced. Yes, we have connectivity into Apple Health and Google Health through APIs and Epic and Cerna creates a huge ecosystem. But as for you know driving material contributions in Q1, no, not yet. But watch this space throughout this fiscal year, ?you know, and Aaron talked about this in his um sort of, oh no, what would get us to the 7%?

What would get us to the 5%?
?You know, that 7% revenue growth, that's about strong execution in our marketing programs and achieving great results. And and five percent is if we don't achieve the great results that our pilot trials have shown us. I'm an optimist, eternal optimist, and I'm I'm a I love Lucky Seven, we're aiming for ?that. Uh but you know it's it's a quarter-in, quarter out fight, and uh we've got a lot going.

No material contribution in Q1, but as we look at fiscal year, I hope to be you know here in twelve months' time talking about some good material contribution from our marketing programs. Anything I missed there,
Aaron?

Passages & reports (15)
  • Craig, it's a it's a great question. And,
  • you
  • know, I I said this last quarter, I think I've said it every quarter the last uh number of…
  • suffocation, sleep apnea, how important it is to treat good sleep and good breathing for g…
  • on.
  • It's middle of funnel where somebody has is aware from their watch, their wearable, or a p…
  • that 63,000 unique clinicians in the primary care area, whether that's an NP, a PA, an MD,…
  • Aura partnership, we're in the tens of thousands. Eight Sleep, we just announced. Yes, we …
  • you
  • know, and Aaron talked about this in his um sort of, oh no, what would get us to the 7%? W…
  • You
  • know, that 7% revenue growth, that's about strong execution in our marketing programs and …
  • that.
  • Uh but you know it's it's a quarter-in, quarter out fight, and uh we've got a lot going. N…
  • Aaron?

Speaker 3

There's such an opportunity on the top of the funnel, like Mick talked about, and so we're laser focused on these critical investments targeting at the middle of the funnel. And this isn't about growth in a quarter or even a year. This is about creating durable growth that's sustainable over time. ?But it's like Mick said, it's going to take some time for some of these programs, the marketing campaigns, the my air stuff that Nick talked about.

It's going to take some time for those to be able to start to contribute.

Passages & reports (3)
  • There's such an opportunity on the top of the funnel, like Mick talked about, and so we're…
  • But
  • it's like Mick said, it's going to take some time for some of these programs, the marketin…

Speaker 0

Thank ?you. Our next question comes from the line of David Rescott with Baird. Please proceed with your question.

Passages & reports (3)
  • Thank
  • you.
  • Our next question comes from the line of David Rescott with Baird. Please proceed with you…

Speaker 4

Great. Thanks for taking the ?the questions here. Um congrats

Passages & reports (3)
  • Great. Thanks for taking the
  • the questions here. Um
  • congrats

Speaker unclear

?on the results.

Passages & reports (1)
  • on the results.

Speaker 2

Um, you know, I I wanted

Passages & reports (1)
  • Um, you know, I I wanted

Speaker unclear

?to ask

Passages & reports (1)
  • to ask

Speaker 4

um, you know, about the uh

Passages & reports (1)
  • um, you know, about the uh

Speaker 2

upcoming

Passages & reports (1)
  • upcoming

Speaker 4

data I I think we're seeing ?uh on the pill ?form of

Passages & reports (5)
  • data I I think we're seeing
  • uh
  • on the pill
  • form
  • of

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 2

GLP one drug and and and it sounds like there's been a pretty consistent, you know, um adherence

Passages & reports (1)
  • GLP one drug and and and it sounds like there's been a pretty consistent, you know, um adh…

Speaker unclear

?rate and and new start rate that you've been calling out every quarter

Passages & reports (1)
  • rate and and new start rate that you've been calling out every quarter

Speaker 4

so far. So,

Passages & reports (1)
  • so far. So,

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 2

know, just

Passages & reports (1)
  • know, just

Speaker 4

wondering um, you know, if at all um there's anything you're considering in in your mind around if or or why or why not, there would be a a different maybe impact as you think about the either the types of patients that could be coming in for ?you know the the pill form a drug um or um you know uh based on where, you know, within which care setting these patients are are typing are attending to come in through, both from you know a headwind, I guess, and then that market expansionary potential that you've talked about in the

Passages & reports (3)
  • wondering um, you know, if at all um there's anything you're considering in in your mind a…
  • you know
  • the the pill form a drug um or um you know uh based on where, you know, within which care …

Speaker unclear

?past perspective. Thank you. Yeah,

Passages & reports (1)
  • past perspective. Thank you. Yeah,

Speaker 2

uh David, thanks. It's a it's a good question. It's got quite a nuanced question. When you think about the injectable GLP ones, they've uh tended to bring in uh a younger and a more female uh demographic into primary care physician and for you know the goal the the advertising that the pharma company is doing is to bring them in for that injectable and so when when I talked about earlier our middle of funnel work it's making sure that PCP is educated about gold standard that they know the only way to 100% eliminate apnea is to create a pneumatic stent that keeps the tongue off the uvula and all the clinical data, and that they are sort of obligated, well, they are obligated to write a script for PAP.

And
?so as we've focused on that, we've actually seen good movement. The pill form, if if I read the latest from from the two major uh pharma companies in this, ?is bringing in a slightly different demographic. You know, they might be slightly more older and slightly uh you know more towards the male side, but we we'll watch that cohort cohort as it comes through.

It tends to be that an older and more male cohort is actually easier for us to get at middle
of funnel. So um but then you look at the adherence rates and the effect effect uh efficacy rates of the pills versus the injectables, and they're slightly lower. So there's sort of puts and takes as we look at this new cohort. I can tell you, you know, we're now up to uh uh many millions of patients.

I think we're up to three point one million patients, uh three million patients in our in our cohort that we're analyzing here, and we separate by uh drug type, by injectable, by pill, early days on the pill, but we're not seeing a material change in in those data. And
as as we get a cohort that's big enough to talk about, if there is some material change, we'll split it out and we'll talk about the different cohort.

If you're asking me my my gut take, I think uh it'll be a slightly more adherent group because it'll be slightly older and slightly less
female, um, because that's but what we've seen over over history. But you know, you don't know until it's there. Um I do think though that the net benefit of bringing someone into the primary care, having someone else pay hundreds, hundred and fifty plus million a year in advertising to bring someone into the funnel is incredible tailwind for us.

Our job every quarter is to fight middle of the funnel, get that prescription, make it easy to get the home sleep apnea test, make it easy to
?get the sleep lab test, make it easy to get that prescription and get on therapy. And then once they've started therapy, that's when Airview, My Air and all the upgrades we talked about earlier today to maximize adherence.

It's a great question, David, thank

Passages & reports (14)
  • uh David, thanks. It's a it's a good question. It's got quite a nuanced question. When you…
  • is doing is to bring them in for that injectable and so when when I talked about earlier o…
  • uvula and all the clinical data, and that they are sort of obligated, well, they are oblig…
  • so
  • as we've focused on that, we've actually seen good movement. The pill form, if if I read t…
  • is
  • bringing in a slightly different demographic. You know, they might be slightly more older …
  • of funnel. So um but then you look at the adherence rates and the effect effect uh efficac…
  • many millions of patients. I think we're up to three point one million patients, uh three …
  • as as we get a cohort that's big enough to talk about, if there is some material change, w…
  • female, um, because that's but what we've seen over over history. But you know, you don't …
  • funnel is incredible tailwind for us. Our job every quarter is to fight middle of the funn…
  • get
  • the sleep lab test, make it easy to get that prescription and get on therapy. And then onc…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Thank you. Our next question comes from the line of Brett Fishman with Key Bank Capital Markets. You may proceed with your question.

Passages & reports (1)
  • Thank you. Our next question comes from the line of Brett Fishman with Key Bank Capital Ma…

Speaker unclear

?Hey guys, thank you

Passages & reports (1)
  • Hey guys, thank you

Speaker 0

so much for taking the ?questions. Um

Passages & reports (3)
  • so much for taking the
  • questions.
  • Um

Speaker unclear

?just thinking about the quarter and rest of your setup,

Passages & reports (1)
  • just thinking about the quarter and rest of your setup,

Speaker 6

Unverified voice label

it you know, it seems ?like you beat pretty nicely versus street and the quarterly guidance on both revenue ?growth and

Passages & reports (5)
  • it you know, it seems
  • like you
  • beat pretty nicely versus street and the quarterly guidance on both revenue
  • growth
  • and

Speaker 2

EPS.

Passages & reports (1)
  • EPS.

Speaker 6

And I know ?it's just the first quarter of

Passages & reports (3)
  • And I know
  • it's just the
  • first quarter of

Speaker 2

the year, but just curious on the decision to maintain full year guidance since this is a new practice for the company. If there's any thought ?around like early year conservatism ?and if we should maybe be thinking about ?the higher ?end of

Passages & reports (9)
  • the year, but just curious on the decision to maintain full year guidance since this is a …
  • around
  • like early year conservatism
  • and
  • if we should maybe be thinking about
  • the
  • higher
  • end
  • of

Speaker unclear

?the ranges as being more likely

Passages & reports (1)
  • the ranges as being more likely

Speaker 6

now ?versus signaling to ?the street that we should really just be lowering ?the rest of the year numbers commensurate with the one Q beat. Thank you so

Passages & reports (7)
  • now
  • versus
  • signaling to
  • the
  • street that we should really just be lowering
  • the
  • rest of the year numbers commensurate with the one Q beat. Thank you so

Speaker unclear

?much. Hey

Passages & reports (1)
  • much. Hey

Speaker 2

Brett, thanks for

Passages & reports (1)
  • Brett, thanks for

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 3

question. Uh you are right, it's early. And so just as a reminder, guiding five to seven percent on a core accounts and currency basis. ?Uh we did seven percent in Q1. And so obviously, towards the high end of that, we're really pleased. It's a solid start to the year, but we're one quarter in. Um, I think just reiterating the the guide at this point is prudent. ?

I
want to reiterate that the most likely outcome is still the midpoint of our guide when we go five to seven. And and I did discuss in some of the prepared remarks some of the more important assumptions that's going to move us towards either the low or the high end of the guide. Um, you know, the net price realization as we roll out our price increases around the world.

And

Passages & reports (6)
  • question. Uh you are right, it's early. And so just as a reminder, guiding five to seven p…
  • Uh
  • we did seven percent in Q1. And so obviously, towards the high end of that, we're really p…
  • I
  • want to reiterate that the most likely outcome is still the midpoint of our guide when we …
  • you know, the net price realization as we roll out our price increases around the world. A…

Speaker 2

as I've mentioned,

Passages & reports (1)
  • as I've mentioned,

Speaker unclear

?that's

Passages & reports (1)
  • that's

Speaker 3

going to build as ?we progress throughout the year, but that it's very modest. Second and really importantly is these new marketing campaigns, the middle of the funnel work that we're doing.

Passages & reports (3)
  • going to build as
  • we
  • progress throughout the year, but that it's very modest. Second and really importantly is …

Speaker 3

But as I mentioned a couple of questions ago, that's going to take some time. And so we're monitoring that closely, and obviously that's going to be more of an H2 type of dynamic. The external environment, you know, we're continuing to see inflation not only on us, but on our customers and just the broader macro environment that our channel is facing. And then just from a phasing perspective, you know, highlighted on the call that we are really benefiting in the first half of the year in rest of world devices in particular.

Our really great repaq fleet renewal in France, that will be a that's a huge
tailwind in Q1 as you see the 13% device growth in the rest of the world, that's going to become a headwind as we go into the back half

Passages & reports (3)
  • But as I mentioned a couple of questions ago, that's going to take some time. And so we're…
  • broader macro environment that our channel is facing. And then just from a phasing perspec…
  • tailwind in Q1 as you see the 13% device growth in the rest of the world, that's going to …

Speaker unclear

?of the year. So look,

Passages & reports (1)
  • of the year. So look,

Speaker 3

we're monitoring all of that really, really closely. And I thought just prudent to reiterate the guide at this point. Then just on the on the earnings side, again, uh obviously a really strong beat uh to start the year, but we're still

Passages & reports (1)
  • we're monitoring all of that really, really closely. And I thought just prudent to reitera…

Speaker 2

only one

Passages & reports (1)
  • only one

Speaker unclear

?quarter

Passages & reports (1)
  • quarter

Speaker 3

through

Passages & reports (1)
  • through

Speaker unclear

?through

Passages & reports (1)
  • through

Speaker 2

four quarters in ?a full

Passages & reports (3)
  • four quarters in
  • a
  • full

Speaker 3

year. Um the team delivered really great productivity

Passages & reports (1)
  • year. Um the team delivered really great productivity

Speaker 2

in the

Passages & reports (1)
  • in the

Speaker unclear

?first quarter. It's

Passages & reports (1)
  • first quarter. It's

Speaker 3

it's great to see the culture of continuous improvement and you know extending beyond supply chain down through the rest of the organization as well. Um, but again, it's it's still early.

Passages & reports (1)
  • it's great to see the culture of continuous improvement and you know extending beyond supp…

Speaker 2

Obviously, we did have ?the benefit of

Passages & reports (3)
  • Obviously, we did have
  • the benefit
  • of

Speaker 3

apnea ?so there's some non-op benefit in ?in the earnings per share. Um, we also had a much more weighted share buyback

Passages & reports (5)
  • apnea
  • so
  • there's some non-op benefit in
  • in
  • the earnings per share. Um, we also had a much more weighted share buyback

Speaker 2

in the first quarter. So we talked about almost

Passages & reports (1)
  • in the first quarter. So we talked about almost

Speaker 3

a billion dollars worth of cash deployed towards share buyback. You saw our WASO come down quite a bit, and so those are some of the dynamics that drove the strength in the first quarter.

Passages & reports (1)
  • a billion dollars worth of cash deployed towards share buyback. You saw our WASO come down…

Speaker 6

Aaron, thank you so much. Super helpful. Appreciate

Passages & reports (1)
  • Aaron, thank you so much. Super helpful. Appreciate

Speaker unclear

?it.

Passages & reports (1)
  • it.

Speaker 0

Thank you. Our next question comes from the line of Laura Sutcliffe with City. You may proceed with your question.

Passages & reports (1)
  • Thank you. Our next question comes from the line of Laura Sutcliffe with City. You may pro…

Speaker 1

Hello, thank you for taking my question. I'd just like to ask about how your portfolio

Passages & reports (1)
  • Hello, thank you for taking my question. I'd just like to ask about how your portfolio

Speaker 7

Unverified voice label

optimization process is

Passages & reports (1)
  • optimization process is

Speaker unclear

?going, if

Passages & reports (1)
  • going, if

Speaker 1

I can. Do you see an abundance of opportunities out there at the moment that fit with the target deal size you've spoken to previously? Your areas of focus, maybe your distribution channels, in your opinion, just keen to see what you what you think is out there.

Passages & reports (1)
  • I can. Do you see an abundance of opportunities out there at the moment that fit with the …

Speaker 2

Laura, it's a great question. And uh obviously ?uh yeah, we've talked about tuck-in acquisitions in that sort of sub 500 million range, sort of 100 to 500 million dollars. And you saw uh last quarter that we closed on an amazing product, Nidra. And just having that sales team come into our headquarters in San Diego and and meet with that team to see the passion they have as a as a startup, it really felt to me like sort of ResMed 1994.

You know, just pre our IPO we've got
?an incredibly fast growth opportunity, a huge market potential. And just so excited about about that Nidra product and what it can do for the four hundred million plus people worldwide with Risless Leg syndrome. But right now let's focus on the 17 million in the United States and the reimbursement and get market access and really make that work in its first market.

So early days on Nidra, but very excited. Yeah, look, we we don't talk about the pipeline. I can tell you that we have minority stakes in a number of companies that we think could become future Bright Trees, future Umbians, future Nidras, future Snaps.

Passages & reports (7)
  • Laura, it's a great question. And uh obviously
  • uh
  • yeah, we've talked about tuck-in acquisitions in that sort of sub 500 million range, sort …
  • see the passion they have as a as a startup, it really felt to me like sort of ResMed 1994…
  • an
  • incredibly fast growth opportunity, a huge market potential. And just so excited about abo…
  • really make that work in its first market. So early days on Nidra, but very excited. Yeah,…

And you know, as those come to the right point where we say, actually, now ResMed is the best owner of that asset. It strategically fits with our sleep and breathing portfolio. It pencils out in the numbers in present value, but also in how it's going to contribute in terms of uh accretion and growth and top line and gross margin and ultimately EPS.

And then thirdly, that there's a cultural fit, that this is a cultural ad to ResMed. It stretches us and takes us to the right direction and has all the foundations around honesty, integrity, cybersecurity, and privacy and so on. And so early days in
this, there's a number of candidates that we look at out there, but the money that we have is not burning a hole in our pocket.

We want to return it to shareholders. We want to invest in RD primarily for growth. We're a product led company.
?And we want to do appropriate marketing as we talked about in the middle of the funnel to make sure people who get aware into the system get through. So nothing to announce right now and as we find more nidras, we'll talk about them and bring them into market.

And but we're actively looking an
amazing portfolio. We have an incredible strategy team has their fingers in a lot of pies, irons in a lot of fires and we'll talk about them as as they come through it. But again I'll reiterate it's tucking acquisitions some five hundred million and it's things that uh align strategically for us in the way the best iron ready asset.

Thanks for the question Laura.

Passages & reports (7)
  • And you know, as those come to the right point where we say, actually, now ResMed is the b…
  • growth and top line and gross margin and ultimately EPS. And then thirdly, that there's a …
  • this, there's a number of candidates that we look at out there, but the money that we have…
  • And
  • we want to do appropriate marketing as we talked about in the middle of the funnel to make…
  • amazing portfolio. We have an incredible strategy team has their fingers in a lot of pies,…
  • way the best iron ready asset. Thanks for the question Laura.

Speaker unclear

?Thank you.

Passages & reports (1)
  • Thank you.

Speaker 0

Thank you. Our next question comes from the line of Anthony Patron with Mizuho ?group. You may proceed with your question.

Passages & reports (3)
  • Thank you. Our next question comes from the line of Anthony Patron with Mizuho
  • group.
  • You may proceed with your question.

Speaker 2

Thanks and

Passages & reports (1)
  • Thanks and

Speaker unclear

?uh congrats here on a shrunk start to the year. But maybe Mick

Passages & reports (1)
  • uh congrats here on a shrunk start to the year. But maybe Mick

Speaker 7

just a little bit on the U.S. competitive landscape I know ?you know it's been a topic for quite some time here. ?You have React Health in and certainly there's chatter there that Phillips may come back. ?But you know, if we have a more robust competitive landscape in the U.S., ?you know, how what is the strategy from ResMed to defend to defend its market share position? ?

You know,
and can can the company really maintain its growth uh trajectory even if the landscape shifts a bit? Thanks.

Passages & reports (11)
  • just a little bit on the U.S. competitive landscape I know
  • you know
  • it's been a topic for quite some time here.
  • You
  • have React Health in and certainly there's chatter there that Phillips may come back.
  • But you
  • know, if we have a more robust competitive landscape in the U.S.,
  • you
  • know, how what is the strategy from ResMed to defend to defend its market share position?
  • You know,
  • and can can the company really maintain its growth uh trajectory even if the landscape shi…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

Anthony, it's it's a great question. Uh and I'll I'll start with this we love competition. ?Uh it's amazing in all ?you know 143 countries worldwide. We have full competition in devices, masks, software, accessories all across the the the the planet there. And and within the US market, incredible competition from every player in masks. ?Uh and you know I look forward to the day where it's every player in devices as well, because uh uh we we love beating competitors no matter where it is.

Um look, I
?uh you know, particularly as we as we think about our market share, yeah, absolutely we can defend our market share. We can even grow our market share in masks and devices in some of the countries. And but I I really don't look back ?at the competition and think, oh gosh, you know, what are those? What's that company doing? What's they what are they looking for?

I look forward. Um, but in terms of what we've created, we've created an ecosystem.
?Uh, if you think about what I took earlier about driving adherence up with our fabrics technology, that's great. And and um it's IP and it's hard to keep up with in that space that's full open competition. But the advances we made in my air that drive adherence rates up to 87%, the advances we've made in upgrading the capability for doctors to get access in their own EHR system, whether it's Epic or CERNA or all scripts, however they want the data, wherever they want the data, they get it.

And so 60, 65% plus of sleep doctors write prescriptions, branded prescriptions for a device. They might write RestMed
on the script, they might write AirSense 11 on the script, but they might also just write AirView, our software on it. And it's a it's an incredible ecosystem that provides lower costs for the HME, lowers labor costs of setup, and incredible value for the doctor, that those 12 minutes they spend with a patient once a year are much more valuable because of all the data they've already got through the digital.

So that's what's created the value, that's what's created an incredible competitive nature out there. But I love I love the competition, I love the players coming there. We're not only going to defend our share,
we're going to grow our share, but more important than that, we're going to grow the market. ?And we're going to find a way to get more patients in that top of funnel and leverage the work of consumer tech ?and big pharma to make sure middle of funnel, we maximize if you know you suffocate, if you've got a prescription, we want to make it seamless and frictionless to start that therapy, and most importantly, stay on that therapy.

Not just a day 90, but day 365, year two, year three, year four for life.

Passages & reports (21)
  • Anthony, it's it's a great question. Uh and I'll I'll start with this we love competition.
  • Uh
  • it's amazing in all
  • you
  • know 143 countries worldwide. We have full competition in devices, masks, software, access…
  • Uh
  • and you know I look forward to the day where it's every player in devices as well, because…
  • uh
  • you know, particularly as we as we think about our market share, yeah, absolutely we can d…
  • at
  • the competition and think, oh gosh, you know, what are those? What's that company doing? W…
  • Uh,
  • if you think about what I took earlier about driving adherence up with our fabrics technol…
  • made in upgrading the capability for doctors to get access in their own EHR system, whethe…
  • on the script, they might write AirSense 11 on the script, but they might also just write …
  • patient once a year are much more valuable because of all the data they've already got thr…
  • we're going to grow our share, but more important than that, we're going to grow the marke…
  • And
  • we're going to find a way to get more patients in that top of funnel and leverage the work…
  • and
  • big pharma to make sure middle of funnel, we maximize if you know you suffocate, if you've…

Speaker 3

I would also add the the work that we're doing and some of the things Mick talked about related to Meyer, and so how do we, beyond just grow the existing installed base, but how do we make sure that we're ensuring that all of our the millions of patients that use our device every single night to help them sleep are getting the appropriate new masks, tubs, tubes throughout the year.

And some of these upgrades that we're starting to implement with Meyer, we think can have a meaningful impact on our resupply program over over time.

Passages & reports (2)
  • I would also add the the work that we're doing and some of the things Mick talked about re…
  • single night to help them sleep are getting the appropriate new masks, tubs, tubes through…

Speaker unclear

?Yeah.

Passages & reports (1)
  • Yeah.

Speaker 0

Thank ?you. Our next question comes from the line of uh Dabin for the Nathan with Goldman Sachs. Please proceed with your question.

Passages & reports (3)
  • Thank
  • you.
  • Our next question comes from the line of uh Dabin for the Nathan with Goldman Sachs. Pleas…

Speaker 4

Yes, thanks.

Passages & reports (1)
  • Yes, thanks.

Speaker 6

Uh morning Nick, Aaron, and Sally. Uh appreciate the comments. Uh question on your mask franchise. Um I guess

Passages & reports (1)
  • Uh morning Nick, Aaron, and Sally. Uh appreciate the comments. Uh question on your mask fr…

Speaker unclear

?I'm trying to understand the success of

Passages & reports (1)
  • I'm trying to understand the success of

Speaker 6

the investment ?into your fabric range. Um clearly you've launched another product there, which I believe is in the

Passages & reports (3)
  • the investment
  • into your fabric range.
  • Um clearly you've launched another product there, which I believe is in the

Speaker 4

full phase category, which is an attractive size. Um could you give us a sense of how that um that range is going please whether ?a mix of your mask sales or even just on your market share, just to give us a

Passages & reports (3)
  • full phase category, which is an attractive size. Um could you give us a sense of how that…
  • a
  • mix of your mask sales or even just on your market share, just to give us a

Speaker unclear

?sense of the uh momentum there. Thanks.

Passages & reports (1)
  • sense of the uh momentum there. Thanks.

Speaker 2

Yeah, Davin, it's a great question. And um I I gotta tell you, you know, having watched seven years of the development of the fabrics technology and experimentation of our primarily Singapore-based fabrics engineering, fabrics design team, to have brought those first market uh masks to market, like the AirTouch N30i and and and now to have the AirTouch F40 in in in play, uh, we've now got real-world data to show a six percent increase in adherence for those first launched, you know, now 12, 18 months in market masks.

And so this isn't just about, oh, it looks sexy, it looks great, it feels comfortable, that first fit,
which it does. And the HMEs love it and the patients love it. They say, Oh, I'm choosing rest fan, I'm choosing the fabric. That's great, because first-time fit does matter. Um, first-time failure is a big issue for many of our competitors. They they have these masks that try to look like ours, they just don't fit. ?

The
patient rejects them immediately. But ours, they don't only like them immediately. Day 90, we're getting uh six percent higher adherence. And we'll produce more and more real-world evidence to show I think that'll be sustainable over time. I think the delta of a fabric mask versus its silicone equivalent will play out in all the areas. As you said, F40, it's an oro nasal breather.

It's about 30% of people breathe through their mouths at night. They need
?uh the pneumatic stent to cover both the uh oro and nasal um parts of the body. And and what's great about that, yeah, it's a high margin, uh high growth area. But more important than that, if we can get fabric, which we can now, to form a seal that moves with you all night. ?

If
you heard my prep remarks, I talked about the contour and moving. Uh every person moves and tosses and turns at night unconsciously, so their body doesn't get, you know, cirrhosis and issues with muscles and so ?on. That movement can hurt. If your mask isn't good, it can come off and disturb the bed partner and not give therapy to you. This mask feels comfortable to start, moves with you all night, and drives higher adherence on the former fabric mask.

So early days with AirTouch F40, there'll be more fabric masks
to come. We're two or three in, and I just love the fact that ResMed is again doing a game-changing technology with IP, but more importantly, manufacturing capability that others can't touch, and scale and distribution that others can't ?touch. Excited about AirTouch F40, early days, launched ?this week. Um, but ?we'll give you updates as ?we go throughout the fiscal year on the whole range of fabric masks.

Passages & reports (22)
  • Yeah, Davin, it's a great question. And um I I gotta tell you, you know, having watched se…
  • to have the AirTouch F40 in in in play, uh, we've now got real-world data to show a six pe…
  • which it does. And the HMEs love it and the patients love it. They say, Oh, I'm choosing r…
  • just don't fit.
  • The
  • patient rejects them immediately. But ours, they don't only like them immediately. Day 90,…
  • the areas. As you said, F40, it's an oro nasal breather. It's about 30% of people breathe …
  • uh
  • the pneumatic stent to cover both the uh oro and nasal um parts of the body. And and what'…
  • If
  • you heard my prep remarks, I talked about the contour and moving. Uh every person moves an…
  • on.
  • That movement can hurt. If your mask isn't good, it can come off and disturb the bed partn…
  • to come. We're two or three in, and I just love the fact that ResMed is again doing a game…
  • touch.
  • Excited about AirTouch F40, early days, launched
  • this week. Um,
  • but
  • we'll give
  • you updates as
  • we
  • go throughout the fiscal year on the whole range of fabric masks.

Speaker 0

Thank you. Our next question comes from the line of Dan Hearin with MST. ?You may proceed with your question.

Passages & reports (3)
  • Thank you. Our next question comes from the line of Dan Hearin with MST.
  • You
  • may proceed with your question.

Speaker 2

Good morning, everyone. Thanks very much.

Passages & reports (1)
  • Good morning, everyone. Thanks very much.

Speaker 6

Look, I was wondering about the US manufacturing initiative, just in terms of capacity ?and unit cost versus the legacy capacity, ?and what sort of drag will down gross margin during ramp

Passages & reports (5)
  • Look, I was wondering about the US manufacturing initiative, just in terms of capacity
  • and unit
  • cost versus the legacy capacity,
  • and
  • what sort of drag will down gross margin during ramp

Speaker 2

up and then at scale?

Passages & reports (1)
  • up and then at scale?

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 2

Dan, it's a great question. And you know, what we look at and and how we're looking at this is uh from all our supply chain work that we did during COVID, during the semiconductor sub uh uh crisis, the supply chain crisis. We found out, you know, we I know this is a known event. We talked about it publicly in 2022. We rented ?a 777 jet from uh Air Canada so we could get ventilators over when FedEx and all those were shutting down, and we just need to get product to our biggest volume market.

And um, and it was devices, masks, and and vents. And so we we never want to be in a position like that,
no matter what happens with perturbations supply chain. Our biggest volume market is the US, and we need to have uh local manufacturing there. So we made that plans and we've been putting those in place. ?And we now have a line to make essence 11s in Atlanta, Georgia.

We have masks and and and cushion accessories and motors that we can make in Calabasas and we're expanding our distribution in Indiana so we can get stuff to people within you know 48 hours around North America. And so these investments are
good. ?Uh Aaron talked in prepared markets. He can make some comments now around uh you know the the the investments of those and how we account for those in our books.

But I can tell you, I look at the delivered, landed, provided cost, and we want to make it equal. We've got a lot of
robotics, we've got a lot of automation, and we can get parts and pieces in and make product in Atlanta so that it's delivered to a customer in the US at the same delivered cost as something that we're transporting by air freight or sea freight on our volume manufacturing in Singapore.

So that's what
we're aiming for. The supply chain team's got the numbers. We're ramping up when we're ready. It also provides us incredible flexibility and capability, not just with supply chain perturbations or tariff perturbations or whatever it might happen in the world. REST Med will be able to make sure everyone in 140 countries gets the product they need at the right time and at the right cost so that we can we can keep our our PL and balance sheet together as well.

Aaron, what did I miss on that?

Passages & reports (13)
  • Dan, it's a great question. And you know, what we look at and and how we're looking at thi…
  • event. We talked about it publicly in 2022. We rented
  • a
  • 777 jet from uh Air Canada so we could get ventilators over when FedEx and all those were …
  • no matter what happens with perturbations supply chain. Our biggest volume market is the U…
  • And
  • we now have a line to make essence 11s in Atlanta, Georgia. We have masks and and and cush…
  • good.
  • Uh
  • Aaron talked in prepared markets. He can make some comments now around uh you know the the…
  • robotics, we've got a lot of automation, and we can get parts and pieces in and make produ…
  • we're aiming for. The supply chain team's got the numbers. We're ramping up when we're rea…
  • product they need at the right time and at the right cost so that we can we can keep our o…

Speaker 3

You hit the key thing, which is that over time we expect to be able to deliver a similar landed cost in the U.S. than what we would get importing. Obviously, there's startup costs. We talk about that, for example, at the Indiana, Indiana Distribution Center, and we'll experience all those startup costs in Q2 and Q3 under utilization, right? As you continue to expand.

But it's a great problem to have. We have uh an ever growing increased demand for our products globally and we have the opportunity to be able to bring manufacturing closer to where the customer is and that's what we're looking to

Passages & reports (2)
  • You hit the key thing, which is that over time we expect to be able to deliver a similar l…
  • and Q3 under utilization, right? As you continue to expand. But it's a great problem to ha…

Speaker unclear

?do.

Passages & reports (1)
  • do.

Speaker 0

Thank ?you. And we are now now at the 16 minute mark so I will turn the uh call uh back to Mick McFarrell for closing marks.

Passages & reports (3)
  • Thank
  • you. And
  • we are now now at the 16 minute mark so I will turn the uh call uh back to Mick McFarrell …

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 2

you Shmali and uh thank you uh to to all of our stakeholders for joining us on the call today, particularly our long-term shareholders. On behalf of the approximately 11,000 West Medians serving people in 144 countries worldwide, I'm pleased we're able to deliver another strong quarter here in Q1 and we'll continue to build value for all of our stakeholders. We look forward to speaking with many of you over the coming days and weeks in more detail.

And I'll turn the call back to Sally to close us out.

Passages & reports (2)
  • you Shmali and uh thank you uh to to all of our stakeholders for joining us on the call to…
  • value for all of our stakeholders. We look forward to speaking with many of you over the c…

Speaker 1

Okay, thank you, Mick. I'll echo Mick's thank you. We appreciate your time and interest. If you have any additional questions, please don't hesitate to reach out directly to investorrelations at resmed.com. Shamali you may now close the call.

Passages & reports (1)
  • Okay, thank you, Mick. I'll echo Mick's thank you. We appreciate your time and interest. I…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you and this concludes today's conference and you may disconnect your lines at this time. We thank you for your participation.

Passages & reports (1)
  • you and this concludes today's conference and you may disconnect your lines at this time. …
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

2 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 2. Unassigned words: 261. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-15T21:17:58.980Z.
Transcript version v1-fce3d15839ca96d9ecba · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.